Andrea Biondi

List of Publications by Year
in descending order

382 papers	31,322 citations	8755 77 h-index	6512 162 g-index
391 all docs	391 docs citations	391 times ranked	37051 citing authors

#	Article	IF	Citations
1	Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. Blood, 2022, 139, 1785-1793.	0.6	28
2	Catch me if you can: how AML and its niche escape immunotherapy. Leukemia, 2022, 36, 13-22.	3.3	66
3	Maturation signatures of conventional dendritic cell subtypes in COVIDâ€19 suggest direct viral sensing. European Journal of Immunology, 2022, 52, 109-122.	1.6	22
4	A primarily clinician's responsibility. Pediatric Blood and Cancer, 2022, 69, e29612.	0.8	0
5	The Impact of a Precision-Based Exercise Intervention in Childhood Hematological Malignancies Evaluated by an Adapted Yo-Yo Intermittent Recovery Test. Cancers, 2022, 14, 1187.	1.7	3
6	Precursor Bâ€cell acute lymphoblastic leukaemiaâ€"a global view. British Journal of Haematology, 2022, 196, 530-547.	1.2	6
7	Similar outcome of tricuspid valve repair and replacement for isolated tricuspid infective endocarditis. Journal of Cardiovascular Medicine, 2022, 23, 406-413.	0.6	0
8	Evaluation of the Pattern of Use of a Pediatric Emergency Department in Italy. Pediatric Emergency Care, 2021, 37, e1494-e1498.	0.5	6
9	Acute myeloid leukemia shapes the bone marrow stromal niche <i>in vivo</i>. Haematologica, 2021, 106, 865-870.	1.7	14
10	Primary immunodeficiencies, autoimmune hyperthyroidism, coeliac disease and systemic lupus erythematosus in childhood immune thrombocytopenia. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 643-651.	0.7	8
11	Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis. Annals of Hematology, 2021, 100, 105-116.	0.8	4
12	Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency. Blood, 2021, 137, 493-499.	0.6	26
13	An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight, 2021, 6, .	2.3	269
14	La Pediatria davanti alla sfida della Medicina di precisione. Medico E Bambino, 2021, 40, 7-8.	0.1	1
15	Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. Lancet Haematology,the, 2021, 8, e55-e66.	2.2	32
16	Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia. HemaSphere, 2021, 5, e543.	1.2	20
17	Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak. Critical Care, 2021, 25, 80.	2.5	63
18	Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. Journal of Clinical Oncology, 2021, 39, 652-662.	0.8	41

#	Article	IF	Citations
19	Acute Rheumatic Fever: Where Do We Stand? An Epidemiological Study in Northern Italy. Frontiers in Medicine, 2021, 8, 621668.	1.2	4
20	Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia. , 2021, 9, e002026.		11
21	Monocyteâ€“macrophage polarization and recruitment pathways in the tumour microenvironment of Bâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2021, 193, 1157-1171.	1.2	15
22	Case Report: Hypomorphic Function and Somatic Reversion in DOCK8 Deficiency in One Patient With Two Novel Variants and Sclerosing Cholangitis. Frontiers in Immunology, 2021, 12, 673487.	2.2	5
23	Childhood cancer in Italy: background, goals, and achievements of the Italian Paediatric Hematology Oncology Association (AIEOP). Tumori, 2021, 107, 370-375.	0.6	11
24	Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants. Blood, 2021, 137, 1980-1984.	0.6	12
25	COVID-19 in Immunosuppressed Children. Frontiers in Pediatrics, 2021, 9, 629240.	0.9	30
26	Chemotherapy induces canalization of cell state in childhood B-cell precursor acute lymphoblastic leukemia. Nature Cancer, 2021, 2, 835-852.	5.7	25
27	Musculoskeletal manifestations of childhood cancer and differential diagnosis with juvenile idiopathic arthritis (ONCOREUM): a multicentre, cross-sectional study. Lancet Rheumatology, The, 2021, 3, e507-e516.	2.2	12
28	Neutralizing typeâ€‘I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVIDâ€19. Immunology and Cell Biology, 2021, 99, 917-921.	1.0	69
29	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science Immunology, 2021, 6, .	5.6	357
30	X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Science Immunology, 2021, 6, .	5.6	267
31	Evidence of treatment benefits in patients with MPSI-Hurler in long-term follow up using a new MRI scoring system. Journal of Pediatrics, 2021, , .	0.9	1
32	Serum anti-MÃ¼llerian hormone as a marker of ovarian reserve after cancer treatment and/or hematopoietic stem cell transplantation in childhood: proposal for a systematic approach to gonadal assessment. European Journal of Endocrinology, 2021, 185, 717-728.	1.9	5
33	â€œGrowth patterns in children with mucopolysaccharidosis type I-Hurler after hematopoietic stem cell transplantation: Comparison with untreated patientsâ€• Molecular Genetics and Metabolism Reports, 2021, 28, 100787.	0.4	3
34	PCR Technology to Identify Minimal Residual Disease. Methods in Molecular Biology, 2021, 2185, 77-94.	0.4	8
35	ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment. Blood Advances, 2021, 5, 5164-5178.	2.5	14
36	Cytokine release syndrome after CAR infusion in pediatric patients with refractory/relapsed B-ALL: is there a role for diclofenac?. Tumori, 2021, , 030089162110533.	0.6	1

#	Article	IF	Citations
37	Intercontinental collaboration in clinical trials for children and adolescents with cancerâ€"A systematic review by ACCELERATE. Cancer Medicine, 2021, 10, 8462-8474.	1.3	8
38	Osteopathic Treatment and Evaluation in the Clinical Setting of Childhood Hematological Malignancies. Cancers, 2021, 13, 6321.	1.7	1
39	An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report. Cancers, 2021, 13, 6148.	1.7	24
40	Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols. Haematologica, 2020, 105, 1887-1894.	1.7	33
41	Rituximab Unveils Hypogammaglobulinemia and Immunodeficiency in Children with Autoimmune Cytopenia. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 273-282.	2.0	41
42	Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial. Leukemia, 2020, 34, 1694-1700.	3.3	24
43	PACSIN2 rs2413739 influence on thiopurine pharmacokinetics: validation studies in pediatric patients. Pharmacogenomics Journal, 2020, 20, 415-425.	0.9	15
44	Impact of COVID-19 on the Pattern of Access to a Pediatric Emergency Department in the Lombardy Region, Italy. Pediatric Emergency Care, 2020, 36, e597-e598.	0.5	17
45	More than an â€˜atypicalâ€™ phenotype: dual molecular diagnosis of autoimmune lymphoproliferative syndrome and Becker muscular dystrophy. British Journal of Haematology, 2020, 191, 291-294.	1.2	4
46	Lymphoblastic predominance of blastic phase in children with chronic myeloid leukaemia treated with imatinib: A report from the I-CML-Ped Study. European Journal of Cancer, 2020, 137, 224-234.	1.3	9
47	Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System. Molecular Therapy, 2020, 28, 1974-1986.	3.7	33
48	The Italian Registry for Primary Immunodeficiencies (Italian Primary Immunodeficiency Network;) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3	2.0	15
49	High EVI1 Expression due to NRIP1/EVI1 Fusion in Therapyâ€related Acute Myeloid Leukemia: Description of the First Pediatric Case. HemaSphere, 2020, 4, e471.	1.2	3
50	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 2020, 370, .	6.0	1,749
51	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020, 370, .	6.0	1,983
52	TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals. Frontiers in Immunology, 2020, 11, 1689.	2.2	63
53	Dexamethasone Stimulation Test in the Diagnostic Work-Up of Growth Hormone Deficiency in Childhood: Clinical Value and Comparison With Insulin-Induced Hypoglycemia. Frontiers in Endocrinology, 2020, 11, 599302.	1.5	2
54	BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy. Haematologica, 2020, 105, 2200-2204.	1.7	24

#	Article	IF	Citations
55	Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?. Cells, 2020, 9, 1337.	1.8	32
56	Singleâ€cell profiling of pediatric Tâ€cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K / Akt and JAKâ€“STAT signaling pathways. Cytometry Part B - Clinical Cytometry, 2020, 98, 491-503.	0.7	13
57	Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols. Leukemia, 2020, 34, 3042-3046.	3.3	13
58	Collateral effects of COVIDâ€19 pandemic in pediatric hematooncology: Fatalities caused by diagnostic delay. Pediatric Blood and Cancer, 2020, 67, e28482.	0.8	26
59	Neonatal combination therapy improves some of the clinical manifestations in the Mucopolysaccharidosis type I murine model. Molecular Genetics and Metabolism, 2020, 130, 197-208.	0.5	10
60	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. New England Journal of Medicine, 2020, 383, 1522-1534.	13.9	1,548
61	Intermittent granulocyte maturation arrest, hypocellular bone marrow, and episodic normal neutrophil count can be associated with SRP54 mutations causing Shwachmanâ€“Diamondâ€like syndrome. British Journal of Haematology, 2020, 189, e171-e174.	1.2	14
62	Early advice on managing children with cancer during the COVIDâ€19 pandemic and a call for sharing experiences. Pediatric Blood and Cancer, 2020, 67, e28327.	0.8	93
63	Proâ€inflammatory cytokines favor the emergence of ETV6â€RUNX1â€positive preâ€leukemic cells in a model of mesenchymal niche. British Journal of Haematology, 2020, 190, 262-273.	1.2	25
64	Prevalence of Immunological Defects in a Cohort of 97 Rubinsteinâ€“Taybi Syndrome Patients. Journal of Clinical Immunology, 2020, 40, 851-860.	2.0	19
65	Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia. British Journal of Haematology, 2020, 188, e101-e105.	1.2	5
66	Dysregulation of NIPBL leads to impaired RUNX1 expression and haematopoietic defects. Journal of Cellular and Molecular Medicine, 2020, 24, 6272-6282.	1.6	8
67	Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in Lombardia, Italy. Estote parati. Bone Marrow Transplantation, 2020, 55, 1900-1905.	1.3	104
68	Prenatal Origin of Pediatric Leukemia: Lessons From Hematopoietic Development. Frontiers in Cell and Developmental Biology, 2020, 8, 618164.	1.8	14
69	Children with cancer in the time of COVIDâ€19: An 8â€week report from the six pediatric oncoâ€hematology centers in Lombardia, Italy. Pediatric Blood and Cancer, 2020, 67, e28410.	0.8	82
70	Germâ€Line TP53ÂMutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition. HemaSphere, 2020, 4, e460.	1.2	2
71	Sleeping Beautyâ€“engineered CAR T cells achieve antileukemic activity without severe toxicities. Journal of Clinical Investigation, 2020, 130, 6021-6033.	3.9	102
72	Location First: Targeting Acute Myeloid Leukemia Within Its Niche. Journal of Clinical Medicine, 2020, 9, 1513.	1.0	22

#	Article	IF	Citations
73	Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. Journal of Clinical Oncology, 2019, 37, 2246-2256.	0.8	186
74	Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10â€“14 years as compared with those aged 15â€“17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study. European Journal of Cancer, 2019, 122, 61-71.	1.3	14
75	A European paediatric cancer mission: aspiration or reality?. Lancet Oncology, The, 2019, 20, 1200-1202.	5.1	10
76	NIPBL: a new player in myeloid cell differentiation. Haematologica, 2019, 104, 1332-1341.	1.7	22
77	Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study. Haematologica, 2019, 104, 1812-1821.	1.7	32
78	Molecular Pathways and Respiratory Involvement in Lysosomal Storage Diseases. International Journal of Molecular Sciences, 2019, 20, 327.	1.8	27
79	Surgical treatment of isolated tricuspid valve infective endocarditis: 25-year results from a multicenter registry. International Journal of Cardiology, 2019, 292, 62-67.	0.8	25
80	Acute myeloid leukaemia niche regulates response to Lâ€asparaginase. British Journal of Haematology, 2019, 186, 420-430.	1.2	18
81	Activin A contributes to the definition of a pro-oncogenic bone marrow microenvironment in t(12;21) preleukemia. Experimental Hematology, 2019, 73, 7-12.e4.	0.2	9
82	Globalization of pediatric research: pharmacological RCTs in Latin America. Italian Journal of Pediatrics, 2019, 45, 29.	1.0	2
83	Evaluation of Technical Issues in a Pilot Multicenter Newborn Screening Program for Sickle Cell Disease. International Journal of Neonatal Screening, 2019, 5, 2.	1.2	4
84	First evidence of a paediatric patient with Cornelia de Lange syndrome with acute lymphoblastic leukaemia. Journal of Clinical Pathology, 2019, 72, 558-561.	1.0	10
85	Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare CancersÂin cooperation with the European Cooperative Study Group for Pediatric Rare Tumors. European Journal of Cancer, 2019, 110, 120-126.	1.3	61
86	Results of a multicenter universal newborn screening program for sickle cell disease in Italy: A call to action. Pediatric Blood and Cancer, 2019, 66, e27657.	0.8	14
87	Late mortality and causes of death among 5-year survivors of childhood cancer diagnosed in the period 1960â€“1999 and registered in the Italian Off-Therapy Registry. European Journal of Cancer, 2019, 110, 86-97.	1.3	36
88	A Simple RNA Target Capture NGS Strategy for Fusion Genes Assessment in the Diagnostics of Pediatric Bâ€cell Acute Lymphoblastic Leukemia. HemaSphere, 2019, 3, e250.	1.2	13
89	Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor. Haematologica, 2019, 104, e13-e16.	1.7	19
90	How I treat infant leukemia. Blood, 2019, 133, 205-214.	0.6	82

#	Article	IF	Citations
91	Modeling Cornelia de Lange syndrome in vitro and in vivo reveals a role for cohesin complex in neuronal survival and differentiation. Human Molecular Genetics, 2019, 28, 64-73.	1.4	20
92	ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells. Haematologica, 2019, 104, 533-545.	1.7	21
93	Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse. Nature Medicine, 2018, 24, 474-483.	15.2	112
94	Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia. Human Gene Therapy, 2018, 29, 602-613.	1.4	35
95	Atalurenâ€driven restoration of Shwachmanâ€Bodianâ€Diamond syndrome protein function in Shwachmanâ€Diamond syndrome bone marrow cells. American Journal of Hematology, 2018, 93, 527-536.	2.0	15
96	Neutropenia, hypogammaglobulinemia, and pneumonia: A case of <scp>WHIM</scp> syndrome. Pediatrics International, 2018, 60, 318-319.	0.2	3
97	Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with highâ€dose imatinib. British Journal of Haematology, 2018, 180, 895-898.	1.2	3
98	<scp>AIEOP</scp>â€<scp>BFM</scp> Consensus Guidelines 2016 for Flow Cytometric Immunophenotyping of Pediatric Acute Lymphoblastic Leukemia. Cytometry Part B - Clinical Cytometry, 2018, 94, 82-93.	0.7	96
99	<scp>TNFRSF</scp>13C (<scp>BAFFR</scp>) positive blasts persist after early treatment and at relapse in childhood Bâ€cell precursor acute lymphoblastic leukaemia. British Journal of Haematology, 2018, 182, 434-436.	1.2	8
100	Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Haematologica, 2018, 103, 107-115.	1.7	68
101	Engineered T cells towards TNFRSF13C (<scp>BAFFR</scp>): a novel strategy to efficiently target Bâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2018, 182, 939-943.	1.2	19
102	IKZF1^{plus} Defines a New Minimal Residual Diseaseâ€“Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2018, 36, 1240-1249.	0.8	194
103	Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000). Journal of Clinical Oncology, 2018, 36, 244-253.	0.8	71
104	Spirometry monitoring in asthmatic children in Lombardy Region, Italy. BMJ Paediatrics Open, 2018, 2, e000334.	0.6	1
105	A new case report of severe mucopolysaccharidosis type VII: diagnosis, treatment with haematopoietic cell transplantation and prenatal diagnosis in a second pregnancy. Italian Journal of Pediatrics, 2018, 44, 128.	1.0	12
106	The new frame for Mucopolysaccharidoses. Italian Journal of Pediatrics, 2018, 44, 117.	1.0	6
107	Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. Lancet Haematology,the, 2018, 5, e641-e652.	2.2	78
108	Heterozygous Mutation in Adenosine Deaminase Gene in a Patient With Severe Lymphopenia Following Corticosteroid Treatment of Autoimmune Hemolytic Anemia. Frontiers in Pediatrics, 2018, 6, 272.	0.9	2

#	Article	IF	Citations
109	Emergency department use by paediatric patients in Lombardy Region, Italy: a population study. BMJ Paediatrics Open, 2018, 2, e000247.	0.6	34
110	Real-Life Management of Children and Adolescents with Chronic Myeloid Leukemia: The Italian Experience. Acta Haematologica, 2018, 140, 105-111.	0.7	5
111	Generic formulations of imatinib for treatment of Philadelphia chromosomeâ€“positive leukemia in pediatric patients. Pediatric Blood and Cancer, 2018, 65, e27431.	0.8	11
112	Mesenchymal stromal cells from ShwachmanâĐDiamond syndrome patients fail to recreate a bone marrow niche inÂvivo and exhibit impaired angiogenesis. British Journal of Haematology, 2018, 182, 114-124.	1.2	13
113	The presence of mutated and deleted <scp>PTEN</scp> is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with <scp>AIEOP</scp>â€<scp>BFM ALL</scp> protocols. British Journal of Haematology, 2018, 182, 705-711.	1.2	30
114	Long-term survivors of childhood cancer: cure and careâ€”the Erice Statement (2006) revised after 10Âyears (2016). Journal of Cancer Survivorship, 2018, 12, 647-650.	1.5	21
115	Rings and Bricks: Expression of Cohesin Components is Dynamic during Development and Adult Life. International Journal of Molecular Sciences, 2018, 19, 438.	1.8	4
116	Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL. Molecular Cancer Therapeutics, 2018, 17, 1705-1716.	1.9	18
117	A novel <scp>EP</scp>300 mutation associated with Rubinsteinâ€Taybi syndrome type 2 presenting as combined immunodeficiency. Pediatric Allergy and Immunology, 2018, 29, 776-781.	1.1	4
118	SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia. Oncotarget, 2018, 9, 22872-22885.	0.8	11
119	Mesenchymal stromal cellâ€“secreted chemerin is a novel immunomodulatory molecule driving the migration of ChemR23-expressing cells. Cytotherapy, 2017, 19, 200-210.	0.3	6
120	Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms. British Journal of Cancer, 2017, 116, 335-343.	2.9	20
121	Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations. Cancer Chemotherapy and Pharmacology, 2017, 79, 1267-1271.	1.1	5
122	Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the <scp>I</scp>nternational <scp>R</scp>egistry for <scp>C</scp>hronic <scp>M</scp>yeloid <scp>L</scp>eukemia in <scp>C</scp>hildren and <scp>A</scp>dolescents. Cancer, 2017, 123, 3609-3616.	2.0	25
123	Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4030-E4039.	3.3	62
124	Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia. Molecular Therapy, 2017, 25, 1933-1945.	3.7	126
125	A predictive model for early mortality after surgical treatment of heart valve or prosthesis infective endocarditis. The EndoSCORE. International Journal of Cardiology, 2017, 241, 97-102.	0.8	45
126	Human umbilical cord blood-borne fibroblasts contain marrow niche precursors that form a bone/marrow organoid in vivo. Development (Cambridge), 2017, 144, 1035-1044.	1.2	22

#	Article	IF	Citations
127	Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies. Human Gene Therapy, 2017, 28, 231-241.	1.4	19
128	Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia. Journal of Autoimmunity, 2017, 85, 141-152.	3.0	14
129	Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents. Haematologica, 2017, 102, 1704-1708.	1.7	40
130	Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL. Blood, 2017, 130, 2146-2149.	0.6	7
131	Neonatal umbilical cord blood transplantation halts skeletal disease progression in the murine model of MPS-I. Scientific Reports, 2017, 7, 9473.	1.6	9
132	Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 2070-2078.	2.0	48
133	Impairment of Retinoic Acid Signaling in Cornelia de Lange Syndrome Fibroblasts. Birth Defects Research, 2017, 109, 1268-1276.	0.8	5
134	Human aplastic anaemiaâ€derived mesenchymal stromal cells form functional haematopoietic stem cell niche in vivo. British Journal of Haematology, 2017, 179, 669-673.	1.2	14
135	High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia. Oncotarget, 2017, 8, 42398-42413.	0.8	19
136	Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform. Oncotarget, 2016, 7, 51581-51597.	0.8	43
137	â€œThere's no Reason whyâ€: A Campaign to Raise Cancer Awareness among Adolescents. Tumori, 2016, 102, 270-275.	0.6	8
138	Hodgkin lymphoma in a patient with mosaic trisomy 18: First clinical observation. American Journal of Medical Genetics, Part A, 2016, 170, 777-780.	0.7	5
139	CyclinD1 Downâ€Regulation and Increased Apoptosis Are Common Features of Cohesinopathies. Journal of Cellular Physiology, 2016, 231, 613-622.	2.0	16
140	Adolescentsâ€™ Health Awareness and Understanding of Cancer and Tumor Prevention: When and Why an Adolescent Decides to Consult a Physician. Pediatric Blood and Cancer, 2016, 63, 1357-1361.	0.8	24
141	Adolescents with Cancer in Italy: Improving Access to National Cooperative Pediatric Oncology Group (AIEOP) Centers. Pediatric Blood and Cancer, 2016, 63, 1116-1119.	0.8	14
142	Paediatric nonâ€Hodgkin lymphoma in low and middle income countries. British Journal of Haematology, 2016, 173, 651-654.	1.2	14
143	Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities. Haematologica, 2016, 101, e95-e99.	1.7	17
144	Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood, 2016, 127, 2101-2112.	0.6	208

#	Article	IF	Citations
145	From Adjustment to Thriving: Exploring Well-Being in Young Adult Survivors of Childhood Cancer and Their Siblings. Journal of Adolescent and Young Adult Oncology, 2016, 5, 330-336.	0.7	5
146	Role of CXCR4-mediated bone marrow colonization in CNS infiltration by T cell acute lymphoblastic leukemia. Journal of Leukocyte Biology, 2016, 99, 1077-1087.	1.5	41
147	Thrombocytopenia and Cornelia de Lange syndrome: Still an enigma?. American Journal of Medical Genetics, Part A, 2016, 170, 130-134.	0.7	4
148	Williams syndrome and mature B-Leukemia: A random association?. European Journal of Medical Genetics, 2016, 59, 634-640.	0.7	9
149	Spiritual Support for Adolescent Cancer Patients: A Survey of Pediatric Oncology Centers in Italy and Spain. Tumori, 2016, 102, 376-380.	0.6	15
150	The SIOPE strategic plan: A European cancer plan for children and adolescents. Journal of Cancer Policy, 2016, 8, 17-32.	0.6	57
151	Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. Lancet Haematology,the, 2016, 3, e80-e86.	2.2	95
152	Development of advanced therapies in Italy: Management models and sustainability in six Italian cell factories. Cytotherapy, 2016, 18, 481-486.	0.3	7
153	Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. Journal of Clinical Oncology, 2016, 34, 919-926.	0.8	111
154	Neonatal cellular and gene therapies for mucopolysaccharidoses: the earlier the better?. Journal of Inherited Metabolic Disease, 2016, 39, 189-202.	1.7	19
155	Genetic predisposition to hemophagocytic lymphohistiocytosis: Report on 500 patients from the Italian registry. Journal of Allergy and Clinical Immunology, 2016, 137, 188-196.e4.	1.5	139
156	Mesenchymal Stromal Cell-Derived PTX3 Promotes Wound Healing via Fibrin Remodeling. Journal of Investigative Dermatology, 2016, 136, 293-300.	0.3	63
157	CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. Oncotarget, 2016, 7, 59260-59272.	0.8	24
158	Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation. Oncotarget, 2016, 7, 82123-82138.	0.8	6
159	Acute Lymphoblastic Leukemia. , 2016, , 561-577.		0
160	Neonatal bone marrow transplantation prevents bone pathology in a mouse model of mucopolysaccharidosis type I. Blood, 2015, 125, 1662-1671.	0.6	37
161	Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia. Haematologica, 2015, 100, e229-e232.	1.7	29
162	Hepatic Granulomatous Lesions Caused by Systemic Bartonella vinsonii subsp. arupensis Infection in a Child. Pediatric Infectious Disease Journal, 2015, 34, 1416-1417.	1.1	6

#	Article	IF	Citations
163	Donor-derived CD19-targeted T cells in allogeneic transplants. Current Opinion in Hematology, 2015, 22, 497-502.	1.2	16
164	LCKover-expression drives STAT5 oncogenic signaling inPAX5translocated BCP-ALL patients. Oncotarget, 2015, 6, 1569-1581.	0.8	17
165	Full GMP-Compliant Validation of Bone Marrow-Derived Human CD133⁺Cells as Advanced Therapy Medicinal Product for Refractory Ischemic Cardiomyopathy. BioMed Research International, 2015, 2015, 1-10.	0.9	6
166	Combined cord blood and bone marrow transplantation from the same human leucocyte antigenâ€identical sibling donor for children with malignant and nonâ€malignant diseases. British Journal of Haematology, 2015, 169, 103-110.	1.2	20
167	Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia. Haematologica, 2015, 100, 295-299.	1.7	49
168	Enzymatic replacement therapy for Hunter disease: Up to 9years experience with 17 patients. Molecular Genetics and Metabolism Reports, 2015, 3, 65-74.	0.4	63
169	miRNA-regulated gene expression differs in celiac disease patients according to the age of presentation. Genes and Nutrition, 2015, 10, 482.	1.2	33
170	Clinical features and outcome of SIL/TAL1-positive T-cell acute lymphoblastic leukemia in children and adolescents: a 10-year experience of the AIEOP group. Haematologica, 2015, 100, e10-e13.	1.7	35
171	Longâ€term results of highâ€dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. British Journal of Haematology, 2015, 170, 398-407.	1.2	34
172	Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. British Journal of Haematology, 2015, 169, 711-718.	1.2	56
173	Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. Journal of Clinical Oncology, 2015, 33, 2938-2948.	0.8	747
174	Development of an algorithm for the management of cervical lymphadenopathy in children: consensus of the Italian Society of Preventive and Social Pediatrics, jointly with the Italian Society of Pediatric Infectious Diseases and the Italian Society of Pediatric Otorhinolaryngology. Expert Review of Anti-Infective Therapy, 2015, 13, 1557-1567.	2.0	31
175	Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention. Expert Review of Hematology, 2015, 8, 57-70.	1.0	30
176	Three novel fusion transcripts of the paired box 5 gene in B-cell precursor acute lymphoblastic leukemia. Haematologica, 2015, 100, e14-e17.	1.7	11
177	Failure of interferon-Î³ pre-treated mesenchymal stem cell treatment in a patient with Crohnâ€™s disease. World Journal of Gastroenterology, 2015, 21, 4379.	1.4	21
178	Childhood acute lymphoblastic leukemia in Nicaragua: Longâ€term results in the context of an international cooperative program. Pediatric Blood and Cancer, 2014, 61, 827-832.	0.8	20
179	Cervical spine malformation in cornelia de lange syndrome: A report of three patients. American Journal of Medical Genetics, Part A, 2014, 164, 1520-1524.	0.7	6
180	AsociaciÃ³n de Hemato-OncologÃa PediÃ¡trica de Centro AmÃ©rica (AHOPCA): A model for sustainable development in pediatric oncology. Pediatric Blood and Cancer, 2014, 61, 345-354.	0.8	76

#	Article	IF	Citations
181	Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants. Italian Journal of Pediatrics, 2014, 40, 65.	1.0	129
182	CD123 AML targeting by chimeric antigen receptors. OncoImmunology, 2014, 3, e28835.	2.1	27
183	Cytoskeletal Regulatory Gene Expression and Migratory Properties of B-cell Progenitors Are Affected by the ETV6â€“RUNX1 Rearrangement. Molecular Cancer Research, 2014, 12, 1796-1806.	1.5	10
184	Comparative analysis of multilineage properties of mesenchymal stromal cells derived from fetal sources shows an advantage of mesenchymal stromal cells isolated from cord blood in chondrogenic differentiation potential. Cytotherapy, 2014, 16, 893-905.	0.3	35
185	Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?. British Journal of Haematology, 2014, 164, 396-408.	1.2	76
186	Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients. Biology of Blood and Marrow Transplantation, 2014, 20, 375-381.	2.0	181
187	RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nature Genetics, 2014, 46, 116-125.	9.4	313
188	Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood, 2014, 123, 70-77.	0.6	189
189	Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood, 2014, 123, 1470-1478.	0.6	69
190	Managing children with chronic myeloid leukaemia (<scp>CML</scp>). British Journal of Haematology, 2014, 167, 33-47.	1.2	100
191	Immunosuppression does not affect human bone marrow mesenchymal stromal cell efficacy after transplantation in traumatized mice brain. Neuropharmacology, 2014, 79, 119-126.	2.0	44
192	Establishment of bone marrow and hematopoietic niches in vivo by reversion of chondrocyte differentiation of human bone marrow stromal cells. Stem Cell Research, 2014, 12, 659-672.	0.3	78
193	Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia. Blood, 2014, 124, 106-110.	0.6	50
194	IKZF1 status as a prognostic feature in BCR-ABL1â€“positive childhood ALL. Blood, 2014, 123, 1691-1698.	0.6	129
195	The authors reply. Critical Care Medicine, 2014, 42, e729-e730.	0.4	0
196	The authors reply. Critical Care Medicine, 2014, 42, e247-e248.	0.4	0
197	Two cases of hepatic adenomas in patients with wolfâ€hirschhorn syndrome: A new rare complication?. American Journal of Medical Genetics, Part A, 2013, 161, 1759-1762.	0.7	13
198	New policies to address the global burden of childhood cancers. Lancet Oncology, The, 2013, 14, e125-e135.	5.1	96

#	Article	IF	Citations
199	Acute myeloid leukemia and novel biological treatments: Monoclonal antibodies and cell-based gene-modified immune effectors. Immunology Letters, 2013, 155, 43-46.	1.1	20
200	Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia. Leukemia, 2013, 27, 1204-1207.	3.3	45
201	Allogeneic mesenchymal stem cell infusion for the stabilization ofÂfocal segmental glomerulosclerosis. Biologicals, 2013, 41, 439-445.	0.5	27
202	Targeting of acute myeloid leukaemia by cytokineâ€induced killer cells redirected with a novel <scp>CD</scp>123â€specific chimeric antigen receptor. British Journal of Haematology, 2013, 161, 389-401.	1.2	186
203	Detection of minimal residual disease in pediatric acute lymphoblastic leukemia. Cytometry Part B - Clinical Cytometry, 2013, 84, 359-369.	0.7	92
204	Linking genomic lesions with minimal residual disease improves prognostic stratification in children with T-cell acute lymphoblastic leukaemia. Leukemia Research, 2013, 37, 928-935.	0.4	16
205	Partial duplication of the <scp>PARK</scp>2 gene in a child with developmental delay and her normal mother: A second report. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 485-486.	1.1	14
206	Novel clinical trials for pediatric leukemias: lessons learned from genomic analyses. Hematology American Society of Hematology Education Program, 2013, 2013, 612-619.	0.9	5
207	What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?. Haematologica, 2013, 98, 1226-1231.	1.7	65
208	Advanced Targeted, Cell and Gene-Therapy Approaches for Pediatric Hematological Malignancies: Results and Future Perspectives. Frontiers in Oncology, 2013, 3, 106.	1.3	5
209	Aorta to right atrial shunt due to the rupture of a degenerative aneurysm of the noncoronary sinus of Valsalva. Journal of Cardiovascular Medicine, 2013, 14, 71-73.	0.6	6
210	A Randomized Controlled Trial of Preoperative Intra-Aortic Balloon Pump in Coronary Patients With Poor Left Ventricular Function Undergoing Coronary Artery Bypass Surgery*. Critical Care Medicine, 2013, 41, 2476-2483.	0.4	57
211	The silent mutational landscape of infant MLLâ€AF4 proâ€B acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2013, 52, 954-960.	1.5	50
212	Germline mosaicism in cornelia de lange syndrome: Dilemmas and risk figures. American Journal of Medical Genetics, Part A, 2013, 161, 1825-1826.	0.7	2
213	A boy with Burkitt lymphoma associated with Noonan syndrome due to a mutation in RAF1. American Journal of Medical Genetics, Part A, 2013, 161, 1401-1404.	0.7	5
214	Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood, 2013, 122, 170-178.	0.6	162
215	The Effects of Propofol and Ketamine on the Cytokine Levels of Children With Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2013, 35, e296-e300.	0.3	8
216	Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica, 2013, 98, 1702-1710.	1.7	121

#	Article	IF	Citations
217	Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "Incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia". Haematologica, 2013, 98, e164-e165.	1.7	16
218	An Attempt to Induce Transient Immunosuppression Pre-Erythrocytapheresis in a Girl with Sickle Cell Disease, a History of Severe Delayed Hemolytic Transfusion Reactions and Need for Hip Prosthesis. Hematology Reports, 2013, 5, e11.	0.3	7
219	Mesenchymal Stromal Cells Do Not Increase the Risk of Viral Reactivation Nor the Severity of Viral Events in Recipients of Allogeneic Stem Cell Transplantation. Stem Cells International, 2012, 2012, 1-6.	1.2	28
220	Comparison of Different Suicide-Gene Strategies for the Safety Improvement of Genetically Manipulated T Cells. Human Gene Therapy Methods, 2012, 23, 376-386.	2.1	102
221	Moral distress in nurses in oncology and haematology units. Nursing Ethics, 2012, 19, 183-195.	1.8	86
222	Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica, 2012, 97, 1582-1593.	1.7	95
223	From Bone Marrow Transplantation to Cellular Therapies: Possible Therapeutic Strategies in Managing Autoimmune Disorders. Current Pharmaceutical Design, 2012, 18, 5776-5781.	0.9	5
224	Protumoral role of monocytes in human B-cell precursor acute lymphoblastic leukemia: involvement of the chemokine CXCL10. Blood, 2012, 119, 227-237.	0.6	59
225	Loss of <scp>CBL</scp> E3â€ligase activity in Bâ€lineage childhood acute lymphoblastic leukaemia. British Journal of Haematology, 2012, 159, 115-119.	1.2	6
226	Glutathione S-transferase homozygous deletions and relapse in childhood acute lymphoblastic leukemia: a novel study design in a large Italian AIEOP cohort. Pharmacogenomics, 2012, 13, 1905-1916.	0.6	16
227	An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia. Cancer Cell, 2012, 22, 683-697.	7.7	213
228	Hurler Disease Bone Marrow Stromal Cells Exhibit Altered Ability to Support Osteoclast Formation. Stem Cells and Development, 2012, 21, 1466-1477.	1.1	24
229	A new report of Cornelia de Lange syndrome associated with split hand and feet. American Journal of Medical Genetics, Part A, 2012, 158A, 2953-2955.	0.7	3
230	Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncology, The, 2012, 13, 936-945.	5.1	282
231	Stem cells in severe infantile spinal muscular atrophy (SMA1). Neuromuscular Disorders, 2012, 22, 1032-1034.	0.3	10
232	Gain-of-function mutations in interleukin-7 receptor-Î± (IL7R) in childhood acute lymphoblastic leukemias. Journal of Experimental Medicine, 2011, 208, 901-908.	4.2	307
233	Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia. Blood, 2011, 118, 5559-5564.	0.6	83
234	Genomic Imbalances Are Confined to Non-Proliferating Cells in Paediatric Patients with Acute Myeloid Leukaemia and a Normal or Incomplete Karyotype. PLoS ONE, 2011, 6, e20607.	1.1	4

#	Article	IF	Citations
235	In Vitro Comparison of Three Different Chimeric Receptor-modified Effector T-cell Populations for Leukemia Cell Therapy. Journal of Immunotherapy, 2011, 34, 469-479.	1.2	19
236	In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Blood, 2011, 117, 4736-4745.	0.6	73
237	Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood, 2011, 118, 2077-2084.	0.6	370
238	Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia. British Journal of Haematology, 2011, 155, 45-52.	1.2	23
239	New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near future. Italian Journal of Pediatrics, 2011, 37, 46.	1.0	8
240	Autologous purified peripheral blood stem cell transplantation compare to chemotherapy in childhood acute lymphoblastic leukemia after lowâ€risk relapse. Pediatric Blood and Cancer, 2011, 57, 654-659.	0.8	7
241	Tâ€cell lymphoblastic lymphoma shows differences and similarities with Tâ€cell acute lymphoblastic leukemia by genomic and gene expression analyses. Genes Chromosomes and Cancer, 2011, 50, 1063-1075.	1.5	44
242	IDUA mutational profiling of a cohort of 102 European patients with mucopolysaccharidosis type I: identification and characterization of 35 novel Î±-L-iduronidase (IDUA) alleles. Human Mutation, 2011, 32, E2189-E2210.	1.1	66
243	Gain-of-function mutations in interleukin-7 receptor-Î± (IL7R) in childhood acute lymphoblastic leukemias. Journal of Experimental Medicine, 2011, 208, 1333-1333.	4.2	6
244	C-kit+ cardiac progenitors exhibit mesenchymal markers and preferential cardiovascular commitment. Cardiovascular Research, 2011, 89, 362-373.	1.8	77
245	Human cord blood CD34+ progenitor cells acquire functional cardiac properties through a cell fusion process. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H1875-H1884.	1.5	29
246	GMPâ€based CD133‹sup›+‹/sup› cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy. Journal of Cellular and Molecular Medicine, 2010, 14, 1619-1634.	1.6	16
247	Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)â€"rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood, 2010, 116, 2644-2650.	0.6	141
248	Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood, 2010, 116, 3013-3022.	0.6	110
249	Characterization of Platelet Lysate Cultured Mesenchymal Stromal Cells and Their Potential Use in Tissue-Engineered Osteogenic Devices for the Treatment of Bone Defects. Tissue Engineering - Part C: Methods, 2010, 16, 201-214.	1.1	53
250	Modulation of antigen expression in Bâ€cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drugâ€induced regulatory phenomenon. Results of the AIEOPâ€BFMâ€ALLâ€FLOWâ€MRDâ€Study Group. Cytometry Part B - Clinical Cytometry, 2010, 78B, 147-153.	0.7	46
251	Identification of immunophenotypic signatures by clustering analysis in pediatric patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia. American Journal of Hematology, 2010, 85, 138-141.	2.0	8
252	Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): Review from an international consensus conference. Pediatric Blood and Cancer, 2010, 54, 872-878.	0.8	22

#	Article	IF	Citations
253	Detection of prognostically relevant genetic abnormalities in childhood Bâ€cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlinâ€FrankfÃ¼rtâ€MÃ¼nster study group. British Journal of Haematology, 2010, 151, 132-142.	1.2	108
254	Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica, 2010, 95, 2144-2152.	1.7	102
255	Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood, 2010, 115, 3206-3214.	0.6	685
256	Platelet-lysate-Expanded Mesenchymal Stromal Cells as a Salvage Therapy for Severe Resistant Graft-versus-Host Disease in a Pediatric Population. Biology of Blood and Marrow Transplantation, 2010, 16, 1293-1301.	2.0	165
257	Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy. Blood Transfusion, 2010, 8, 63-5.	0.3	35
258	Acute Promyelocytic Leukaemia. , 2010, , 83-108.		0
259	Dissection of PIM serine/threonine kinases in FLT3-ITDâ€“induced leukemogenesis reveals PIM1 as regulator of CXCL12â€“CXCR4-mediated homing and migration. Journal of Experimental Medicine, 2009, 206, 1957-1970.	4.2	128
260	A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups. Haematologica, 2009, 94, 781-789.	1.7	50
261	Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow. Journal of Clinical Oncology, 2009, 27, 5168-5174.	0.8	247
262	ETV6â€“RUNX1 fusion gene and additional genetic changes in infant leukemia: a genome-wide analysis. Cancer Genetics and Cytogenetics, 2009, 193, 86-92.	1.0	6
263	Integration of genomic and gene expression data of childhood ALL without known aberrations identifies subgroups with specific genetic hallmarks. Genes Chromosomes and Cancer, 2009, 48, 22-38.	1.5	62
264	Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias. Cancer Chemotherapy and Pharmacology, 2009, 63, 563-566.	1.1	14
265	Tailoring treatment strategy for acute promyelocytic leukemia in lowâ€income countries. Pediatric Blood and Cancer, 2009, 53, 303-305.	0.8	4
266	Successful Application of OPLSâ€DA for the Discrimination of Wildâ€Type and Mutated Cells in Acute Lymphoblastic Leukemia. QSAR and Combinatorial Science, 2009, 28, 822-828.	1.5	9
267	IGH and IGK gene rearrangements as PCR targets for pediatric Burkitt's lymphoma and mature B-ALL MRD analysis. Laboratory Investigation, 2009, 89, 1182-1186.	1.7	23
268	A case of Philadelphia Positive Acute Lymphoblastic Leukaemia with three different phenotypic lineage, each one presenting the same BCR-ABL hybrid transcript. Leukemia Research, 2009, 33, e175-e177.	0.4	0
269	The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs. Cytotherapy, 2009, 11, 403-413.	0.3	30
270	Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncology, The, 2009, 10, 147-156.	5.1	850

#	Article	IF	Citations
271	Regulatory T Cells and Extracorporeal Photochemotherapy: Correlation With Clinical Response and Decreased Frequency of Proinflammatory T Cells. Transplantation, 2009, 87, 1422-1425.	0.5	70
272	Interleukin-17â€“Producing T-Helper Cells as New Potential Player Mediating Graft-Versus-Host Disease in Patients Undergoing Allogeneic Stem-Cell Transplantation. Transplantation, 2009, 88, 1261-1272.	0.5	108
273	Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. Blood, 2009, 114, 3764-3768.	0.6	78
274	Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic Bâ€cell precursor acute lymphoblastic leukemia cells. Cytometry Part B - Clinical Cytometry, 2008, 74B, 150-155.	0.7	51
275	Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible. Cytometry Part B - Clinical Cytometry, 2008, 74B, 331-340.	0.7	132
276	Isolation of monocytes from leukapheretic products for largeâ€scale GMPâ€grade generation of cytomegalovirusâ€specific Tâ€cell lines by means of an automated elutriation device. Transfusion, 2008, 48, 1644-1649.	0.8	11
277	Characterization of migratory activity and cytokine profile of helper and cytotoxic CMV-specific T-cell lines expanded by a selective peptide library. Experimental Hematology, 2008, 36, 473-485.	0.2	5
278	Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet, The, 2008, 372, 1484-1492.	6.3	318
279	Long-Term Results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: Insight on the Prognostic Value of DNA Index in the Framework of Berlin-Frankfurt-Muensterâ€“Based Chemotherapy. Journal of Clinical Oncology, 2008, 26, 283-289.	0.8	69
280	Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. Journal of Experimental Medicine, 2008, 205, 751-758.	4.2	318
281	PAX5/TEL Acts as a Transcriptional Repressor Causing Down-modulation of CD19, Enhances Migration to CXCL12, and Confers Survival Advantage in pre-BI Cells. Cancer Research, 2008, 68, 181-189.	0.4	49
282	PTX3 as a Potential Novel Tool for the Diagnosis and Monitoring of Pulmonary Fungal Infections in Immuno-compromised Pediatric Patients. Journal of Pediatric Hematology/Oncology, 2008, 30, 881-885.	0.3	27
283	Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica, 2007, 92, 952-959.	1.7	165
284	Structural Analysis Identifies Imidazo[1,2-b]Pyridazines as PIM Kinase Inhibitors with In vitro Antileukemic Activity. Cancer Research, 2007, 67, 6916-6924.	0.4	183
285	Effects of plasma transfusion on hepcidin production in human congenital hypotransferrinemia. Haematologica, 2007, 92, 1407-1410.	1.7	41
286	Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies. Haematologica, 2007, 92, 381-388.	1.7	31
287	Extracorporeal Photochemotherapy Is Accompanied by Increasing Levels of Circulating CD4+CD25+GITR+Foxp3+CD62L+ Functional Regulatory T-Cells in Patients With Graft-Versus-Host Disease. Transplantation, 2007, 84, 31-39.	0.5	136
288	A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet, The, 2007, 370, 240-250.	6.3	547

#	Article	IF	Citations
289	Abnormally expanded proâ€B hematogones associated with congenital cytomegalovirus infection. American Journal of Hematology, 2007, 82, 934-936.	2.0	14
290	Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-Î¶ activating signal. Experimental Hematology, 2007, 35, 1388-1397.	0.2	49
291	Acute Lymphoblastic Leukemia. , 2007, , 337-347.		1
292	TEL/ARG induces cytoskeletal abnormalities in 293T cells. Cancer Letters, 2006, 241, 79-86.	3.2	4
293	Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood, 2006, 107, 4514-4523.	0.6	238
294	Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. Experimental Hematology, 2006, 34, 1218-1228.	0.2	60
295	Monitoring of minimal residual disease in leukemia, advantages and pitfalls. Annals of Medicine, 2006, 38, 512-521.	1.5	15
296	Minimal residual disease. , 2006, , 679-706.		1
297	GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood, 2005, 106, 447-453.	0.6	196
298	Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood, 2005, 106, 1419-1422.	0.6	152
299	Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate. Transfusion, 2005, 45, 1214-1220.	0.8	14
300	Somatic PTPN11 mutations in childhood acute myeloid leukaemia. British Journal of Haematology, 2005, 129, 333-339.	1.2	78
301	Reconstitution of lymphocyte subpopulations in children with inherited metabolic storage diseases after haematopoietic cell transplantation. British Journal of Haematology, 2005, 130, 249-255.	1.2	14
302	Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. Cancer Immunology, Immunotherapy, 2005, 54, 273-286.	2.0	17
303	CD34+ Stem Cell Recovery After Positive Selection of "Overloaded" Immunomagnetic Columns. Stem Cells and Development, 2005, 14, 740-743.	1.1	12
304	Immunogenotype Changes Prevail in Relapses of Young Children with TEL-AML1-Positive Acute Lymphoblastic Leukemia and Derive Mainly from Clonal Selection. Clinical Cancer Research, 2005, 11, 7720-7727.	3.2	33
305	A wide role for NOTCH1 signaling in acute leukemia. Cancer Letters, 2005, 219, 113-120.	3.2	66
306	WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?. European Journal of Haematology, 2004, 73, 25-28.	1.1	24

#	Article	IF	Citations
307	Identification of preleukemic precursors of hyperdiploid acute lymphoblastic leukemia in cord blood. Genes Chromosomes and Cancer, 2004, 40, 38-43.	1.5	78
308	Potential use of CD40 ligand for immunotherapy of childhood B-cell precursor acute lymphoblastic leukaemia. Best Practice and Research in Clinical Haematology, 2004, 17, 465-477.	0.7	8
309	Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood, 2004, 103, 2358-2362.	0.6	64
310	CD40 activation of BCP-ALL cells generates IL-10â€“producing, IL-12â€“defective APCs that induce allogeneic T-cell anergy. Blood, 2004, 104, 744-751.	0.6	32
311	Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood, 2004, 104, 307-313.	0.6	265
312	Heterogeneity of the 7q36 breakpoints in the t(7;12) involvingETV6 in infant leukemia. Genes Chromosomes and Cancer, 2003, 38, 191-200.	1.5	30
313	FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia. British Journal of Haematology, 2003, 120, 89-92.	1.2	56
314	Genotypes of the glutathione S-transferase superfamily do not correlate with outcome of childhood acute lymphoblastic leukemia. Leukemia, 2003, 17, 981-983.	3.3	12
315	Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation. Leukemia, 2003, 17, 2247-2248.	3.3	20
316	Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2003, 21, 4642-4649.	0.8	2,425
317	Cross-Linking of the Mannose Receptor on Monocyte-Derived Dendritic Cells Activates an Anti-Inflammatory Immunosuppressive Program. Journal of Immunology, 2003, 171, 4552-4560.	0.4	334
318	Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood, 2003, 102, 981-986.	0.6	270
319	Combined expression of pTÎ± and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3788-3793.	3.3	184
320	Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood, 2002, 99, 2541-2544.	0.6	110
321	Monitoring minimal residual disease using chromosomal translocations in childhood ALL. Best Practice and Research in Clinical Haematology, 2002, 15, 21-35.	0.7	16
322	Results of minimal residual disease (MRD) evaluation and MRD-based treatment stratification in childhood ALL. Best Practice and Research in Clinical Haematology, 2002, 15, 623-638.	0.7	10
323	A Human Immunodeficiency Virus Type 1polGene-Derived Sequence (cPPT/CTS) Increases the Efficiency of Transduction of Human Nondividing Monocytes and T Lymphocytes by Lentiviral Vectors. Human Gene Therapy, 2002, 13, 1793-1807.	1.4	56
324	Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet, The, 2002, 359, 1909-1915.	6.3	338

#	Article	IF	Citations
325	A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood â€˜high-riskâ€™ acute lymphoblastic leukaemia: a study of the AIEOP group. British Journal of Haematology, 2002, 118, 741-747.	1.2	18
326	Molecular characterization of a new recombination of the SIL/TAL-1 locus in a child with T-cell acute lymphoblastic leukaemia. British Journal of Haematology, 2002, 118, 1011-1018.	1.2	14
327	Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response. British Journal of Haematology, 2002, 119, 445-453.	1.2	34
328	Commitment of juvenile myelo-monocytic (JMML) leukemic cells to spontaneously differentiate into dendritic cells. The Hematology Journal, 2002, 3, 302-310.	2.0	6
329	Promoter Analysis of TFPT (FB1), a Molecular Partner of TCF3 (E2A) in Childhood Acute Lymphoblastic Leukemia. Biochemical and Biophysical Research Communications, 2001, 288, 1250-1257.	1.0	10
330	Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet, The, 2001, 358, 1239-1241.	6.3	199
331	Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t(4;11) ALL. Oncogene, 2001, 20, 2900-2907.	2.6	76
332	Familial partial monosomy 7 and myelodysplasia. Cancer Genetics and Cytogenetics, 2001, 124, 147-151.	1.0	38
333	Case of congenital hypotransferrinemia suggests that tissue hypoxia during fetal development may cause hypospadias. American Journal of Medical Genetics Part A, 2000, 95, 287-287.	2.4	10
334	Association of gastric and Waldeyer's ring lymphoma: a molecular study. , 2000, 18, 15-19.		10
335	t(7;12)(q36;p13), a new recurrent translocation involvingETV6 in infant leukemia. Genes Chromosomes and Cancer, 2000, 29, 325-332.	1.5	60
336	Deletion of parental GST genes as a possible susceptibility factor in the etiology of infant leukemia. Leukemia Research, 2000, 24, 971-974.	0.4	16
337	Biological and therapeutic aspects of infant leukemia. Blood, 2000, 96, 24-33.	0.6	358
338	Microclustering ofTEL-AML1 translocation breakpoints in childhood acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2000, 29, 219-228.	1.5	53
339	Genetic Modification of Human T Cells with CD20: A Strategy to Purify and Lyse Transduced Cells with Anti-CD20 Antibodies. Human Gene Therapy, 2000, 11, 611-620.	1.4	126
340	Genetic Diagnosis and Molecular Monitoring in the Management of Acute Promyelocytic Leukemia. Blood, 1999, 94, 12-22.	0.6	193
341	Therapy of Molecular Relapse in Acute Promyelocytic Leukemia. Blood, 1999, 94, 2225-2229.	0.6	217
342	Immunoglobulin Light Chain Kappa Deletion Rearrangement as a Marker of Clonality in Mantle Cell Lymphoma. Leukemia and Lymphoma, 1999, 36, 147-150.	0.6	13

#	Article	IF	Citations
343	Characterization of the human myeloid leukemia-derived cell line GF-D8 by multiplex fluorescence in situ hybridization, subtelomeric probes, and comparative genomic hybridization. , 1999, 24, 213-221.		34
344	Delineation of multiple deleted regions in 7q in myeloid disorders. , 1999, 25, 384-392.		65
345	Fusion of ETV6 to the Caudal-Related Homeobox Gene CDX2 in Acute Myeloid Leukemia With the t(12;13)(p13;q12). Blood, 1999, 93, 1025-1031.	0.6	7
346	The Tyrosine Kinase Abl-Related Gene ARG Is Fused toETV6 in an AML-M4Eo Patient With a t(1;12)(q25;p13): Molecular Cloning of Both Reciprocal Transcripts. Blood, 1999, 94, 4370-4373.	0.6	7
347	Extramedullary involvement in patients with acute promyelocytic leukemia. Cancer, 1998, 83, 1522-1528.	2.0	66
348	Identification of new partner chromosomes involved in fusions with theETV6 (TEL) gene in hematologic malignancies. , 1998, 21, 223-229.		35
349	Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. British Journal of Haematology, 1998, 102, 1035-1041.	1.2	184
350	Rapid retroviral infection of human haemopoietic cells of different lineages: efficient transfer in fresh T cells. British Journal of Haematology, 1998, 103, 449-461.	1.2	22
351	Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet, The, 1998, 352, 1731-1738.	6.3	876
352	Molecular Analysis of the Progression fromHelicobacter pyloriâ€“Associated Chronic Gastritis to Mucosa-Associated Lymphoid-Tissue Lymphoma of the Stomach. New England Journal of Medicine, 1998, 338, 804-810.	13.9	230
353	Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RARÎ± Fusion Gene in Patients With Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter â€œAIDAâ€•Trial. Blood, 1998, 92, 784-789.	0.6	266
354	Innovative Two-Step Negative Selection of Granulocyte Colony-Stimulating Factorâ€“Mobilized Circulating Progenitor Cells: Adequacy for Autologous and Allogeneic Transplantation. Blood, 1998, 91, 2189-2196.	0.6	40
355	Expression of Myeloid Markers Lacks Prognostic Impact in Children Treated for Acute Lymphoblastic Leukemia: Italian Experience in AIEOP-ALL 88-91 Studies. Blood, 1998, 92, 795-801.	0.6	1
356	Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+Leukemic Cells and Induces Apoptosis. Blood Cells, Molecules, and Diseases, 1997, 23, 380-394.	0.6	273
357	Identification of Two Novel Isoforms of the ZNF162 Gene: A Growing Family of Signal Transduction and Activator of RNA Proteins. Genomics, 1997, 42, 268-277.	1.3	11
358	Immunocytochemical Diagnosis of Acute Promyelocytic Leukemia (M3) With the Monoclonal Antibody PG-M3 (Anti-PML). Blood, 1997, 90, 4046-4053.	0.6	128
359	A human acute lymphoblastic leukemia line with the T(4;11) translocation as a model of minimal residual disease in SCID mice. Leukemia Research, 1997, 21, 1107-1114.	0.4	18
360	Immunoglobulin heavy chain Diversity genes rearrangement pattern indicates that MALTâ€type gastric lymphoma B cells have undergone an antigen selection process. British Journal of Haematology, 1997, 97, 830-836.	1.2	41

#	Article	IF	Citations
361	Multigenetic lesions in infant acute leukaemias: correlations with ALL-1 gene status. British Journal of Haematology, 1997, 96, 308-313.	1.2	10
362	Inhibition of Granulocyte-Macrophage Colony-Stimulating Factor Prevents Dissemination and Induces Remission of Juvenile Myelomonocytic Leukemia in Engrafted Immunodeficient Mice. Blood, 1997, 90, 4910-4917.	0.6	6
363	Juvenile Myelomonocytic Leukemia. Blood, 1997, 90, 479-488.	0.6	52
364	Incidence and Clinical Relevance of TEL/AML1 Fusion Genes in Children With Acute Lymphoblastic Leukemia Enrolled in the German and Italian Multicenter Therapy Trials. Blood, 1997, 90, 571-577.	0.6	11
365	Molecular Diagnosis and Clinical Relevance of t(9;22), t(4;ll) and t(l;19) Chromosome Abnormalities in a Consecutive Group of 141 Adult Patients with Acute Lymphoblastic Leukemia. Leukemia and Lymphoma, 1996, 21, 457-466.	0.6	28
366	Detection of the breakpoint cluster region-ABL fusion in chronic myeloid leukemia with variant Philadelphia chromosome translocations by in situ hybridization. Cancer Genetics and Cytogenetics, 1996, 89, 153-156.	1.0	5
367	Molecular diagnosis and monitoring of acute myeloid leukemia. Leukemia Research, 1996, 20, 801-807.	0.4	19
368	Reverse transcriptase/polymerase chain reaction followâ€up and minimal residual disease detection in t(1;19)â€positive acute lymphoblastic leukaemia. British Journal of Haematology, 1996, 92, 653-658.	1.2	24
369	Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALLâ€1/AFâ€4 positiveâ€acute lymphoblastic leukaemia. British Journal of Haematology, 1996, 92, 659-664.	1.2	39
370	A (15;17) translocation not associated with acute promyelocytic leukaemia. British Journal of Haematology, 1996, 95, 706-709.	1.2	15
371	Identification of chromosomal rearrangements in the human myeloid leukemia cell line GF-D8 by dual-colour fluorescencein situ hybridization. Hematological Oncology, 1995, 13, 177-183.	0.8	0
372	Establishment of human acute myelogenous leukemia lines secreting interleukin-1Î² in SCID mice. International Journal of Cancer, 1995, 61, 280-285.	2.3	14
373	Clinical Relevance of the PML/RAR-a Gene Rearrangement in Acute Promyelocytic Leukaemia. Leukemia and Lymphoma, 1994, 12, 327-332.	0.6	10
374	Analysis of p53 gene mutations in acute myeloid leukemia. American Journal of Hematology, 1994, 46, 304-309.	2.0	36
375	Polymerase chain reaction (PCR) approach for the evaluation of minimal residual disease in acute leukemia. Stem Cells, 1994, 12, 394-401.	1.4	12
376	Reciprocal translocation t(12;13)(p13;q14) in acute nonlymphoblastic leukemia: Report and cytogenetic analysis of two cases. Cancer Genetics and Cytogenetics, 1994, 77, 106-110.	1.0	13
377	Double target in situ hybridization applied to the study of numerical aberrations in childhood acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 1994, 73, 103-108.	1.0	9
378	Expression and modulation of a mononuclear phagocyte differentiation antigen (PAM-1) during in vitro maturation of peripheral blood monocytes. International Journal of Clinical and Laboratory Research, 1993, 23, 83-87.	1.0	6

#	Article	IF	Citations
379	Frequency of RAS and p53 Mutations in Acute Promyelocytic Leukemias. Leukemia and Lymphoma, 1993, 11, 405-410.	0.6	31
380	Minimal residual disease. , 0, , 632-659.		0
381	Lessons After the Early Management of the COVID-19 Outbreak in a Pediatric Transplant and Hemato-Oncology Center Embedded within a COVID-19 Dedicated Hospital in Lombardia, Italy. <i>Estote Parati.</i> (Be Ready.). SSRN Electronic Journal, 0, , .	0.4	8
382	A Treatment Protocol with Imatinib and Intensive Chemotherapy for Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia: A Single-Arm, Intergroup Study (Esphall 2010). SSRN Electronic Journal, 0, , .	0.4	0